Breaking Finance News

A statement released earlier today by Vetr Inc. about Illumina, Inc. (NASDAQ:ILMN) raises the target price to $165.56

Having a price of $138.98, Illumina, Inc. (NASDAQ:ILMN) traded 0.61% higher on the day. With the last stock price close down -11.57% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Illumina, Inc. has recorded a 50-day average of $171.14 and a two hundred day average of $156.05. Volume of trade was up over the average, with 1,468,694 shares of ILMN changing hands over the typical 1,246,740

Illumina, Inc. (NASDAQ:ILMN) had its stock price target bumped up to $165.56 by Vetr Inc. in an issued report released 10/11/2016. The raised target suggests a potential upside of 0.19% based on the company's previous stock price.

See Chart Below

Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. has a 52 week low of $127.10 and a 52 week high of $196.47 with a PE ratio of 47.26 The company’s market cap is currently $0.

A total of 19 analysts have released a report on Illumina, Inc.. Four analysts rating the company a strong buy, 4 brokerages rating the stock a buy, 15 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell with a average stock price target of $154.53.

Brief Synopsis About Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. (Illumina) offers sequencing and array-based solutions for genetic analysis. The Company's products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company's customers include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. It provides sample-to-answer solutions to its customers in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. It provides reproductive-health solutions, including preimplantation genetic screening and diagnosis, noninvasive prenatal testing, and neonatal and genetic health testing. It also provides whole-genome sequencing, genotyping and NIPT services. It has operations in the United States, Europe, Asia-Pacific and other markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.